Skip to main content
Offering
Offering
Integrated Biologics
Integrated Biologics
Expression Technologies
Expression Technologies
GS Xceed® Gene Expression System
GS piggyBac® Transposon Technology
GS Effex® Cell Line
GS Discovery® Transient Expression
bYlok® Bispecific Pairing Technology
XS Technologies®
Technical Support
Early Derisking and Optimization
Early Derisking and Optimization
Developability Assessment
Manufacturability Assessment
Antibody Humanization and Deimmunization
Protein Engineering
Potency Assessment
Immunogenicity / Immunotoxicity Assessment
Rapid Host Screen and Early Protein Expression
Non-GMP Manufacture
Epibase® in vitro and in silico Screening
Mammalian Biopharmaceutical Services
Mammalian Biopharmaceutical Services
Ibex® Design mAbs DNA-to-IND Program
Ibex® Design Bispecifics DNA-to-IND Program
Ibex® Design Scaffolds and other Recombinant Proteins
Cell Line Development
Tailored License Application Program
Process Development
Analytical Development
Drug Substance Manufacturing
Parenteral Drug Product Services
Parenteral Drug Product Services
Clinical Technology Transfers
Biologics Formulatability
Product Formulation Development
Analytics
Process Development
Biologics Special Services
Drug Product Manufacture
Large-scale Manufacturing Expansion
Biologics Regulatory Services
Knowledge Center
Advanced Synthesis
Advanced Synthesis
Small Molecules
Small Molecules
Drug Substance/API Services
Drug Substance/API Services
Early Phase Small Molecule Development Services
API Support for Early Phase Development
AI-Enabled Route Scouting Service
Solid Form Drug Services
PBPK Modeling Services
Pharmaceutical Method Development
Commercial API Manufacturing Services
Highly Potent API Technologies
Highly Potent API Technologies
HPAPI Handling and Development
HPAPI Manufacturing | Low & High Potency
ADC Clinical and Commercial Manufacturing
ADC Payload Product Development
Particle Engineering
Particle Engineering
Solid Dispersion Technology
Bioavailability Enhancement
Spray-Dried Dispersion Technology
Micronization and Jet Milling
Hot Melt Extrusion
Drug Product
Drug Product
SimpliFiH® Solutions
Drug Product Technologies
Drug Product Technologies
Specialized Drug Product Development
Micro-dosing for Early Human Clinical Studies
Clinical Trial Material Manufacture, Supply
Clinical Bottling, Labelling and Supply
Formulation and Development
Design and Preformulation Development
Drug Development Workflow & Pharmaceutical Process Optimization
Pediatric Drug Product Development
Inhalation Formulation Development
Integrated Offerings
Regulatory Affairs CMC Services
Regulatory Affairs CMC Services
CMC Development Services | CMC Regulatory Submissions
Bioconjugates Services
Bioconjugates Services
Early Development Bioconjugates | ADCs
ADC Drug Substance Manufacturing
Pharmaceutical, ADC Analytical Services
Targeting Agent and Carrier Protein
ADC Process Development
Ibex® Design ADC, DNA-to-IND Program
Knowledge Center
Specialized Modalities
Specialized Modalities
Cell & Gene
Cell & Gene
Process Development
cGMP Manufacturing
Allogeneic
Autologous
Viral Vectors
Exosomes
Cocoon® Platform
Microbial
Microbial
Microbial Strain Development
Process Development
Drug Substance Manufacturing
Analytical Development
mRNA/LNP
mRNA/LNP
Process Development
Analytical Services
mRNA Manufacturing
Lipid Nanoparticles Encapsulation
Bioscience Products
Knowledge Center
Knowledge Center
Company
Company
About Us
About Us
Our One Lonza Strategy
Our Leadership
Our Leadership
Executive Committee
Board of Directors
Board Committees
Our History
Our Locations
News and Media
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
A View On - Lonza Podcast
Journalist Inquiries
Investor Relations
Investor Relations
Shareholders and Stock Information
Shareholders and Stock Information
Consensus and Analysts
Bond Investors and Credit Information
Investor FAQ
Share Buyback
Agenda and Events
Reporting and Presentations
Corporate Governance
Ethics and Compliance
Investor Inquiries and Feedback
Sustainability
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Careers
Careers
Welcome to Lonza
Life at Lonza
Employee Benefits
Early Career Opportunities
Inclusion, Diversity and Belonging
Join Our Talent Community
Contact
Search
Cancel
Home
Knowledge Center
Connecting Clinic and Commercial Biopharma Manufacturing
06 Sep 2021
Connecting Clinic and Commercial Biopharma Manufacturing
You may also be interested in:
Mammalian
Commercial Supply Services
Manufacturing: GMP Drug Substance
Manufacturing: GMP Drug Product
Watch this video
Watch now
Latest briefing from the Knowledge Center
Article
Navigating the nitrosamine challenge: A Q&A with Lonza experts
Q: Why have nitrosamines become such a significant issue in the pharmaceutical...
Article
Nitrosamines: assessing the risk to pharma products
White paper
Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide...
Bioconjugates are no longer just for cancer therapies. This paper reveals how innovative...
Webinar (on-demand)
Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing
Revolutionizing CAR T Therapy: Insights from New Zealand’s Breakthrough Webinar Discover how...
Article
From Molecule to Medicine: overcoming development challenges with the right CDMO partner
Publication
Systematic Development of a Detergent Toolbox as an Alternative to Triton X-100
In biomanufacturing, detergents are essential for inactivating enveloped viruses during protein...
White paper
Transferring your cell line with confidence
This white paper explores flexible, data-driven strategies that help streamline biologics...
Article
Partnering for Innovation: Lonza Supports a UK Biotech Developing an Entirely New Modality with...
Epsilogen CEO, Tim Wilson, shares his company’s experience finding the right CDMO partner, willing...
Article
Lonza’s Expertise and Technical Appetite Help Epsilogen Bring the First IgE Therapeutic into the...
Tim Wilson, CEO of London-based biotech Epsilogen, discusses the company’s journey to develop a...
Article
Q&A: Getting it right first time - the importance of early expression vector design
In this interview, Lonza’s Dr. Peter O’Callaghan (Senior Director, Head of Expression System...
Technical/Service brief
GS Gene Expression System: reliability today, innovation for tomorrow
Emerging and small biotechs play a critical role in driving scientific innovation, often advancing...
Webinar (on-demand)
Future-proofing gene therapy: scalable AAV solutions and non-viral innovations
As gene therapy moves toward broader commercialization, the pressure to streamline production and...
Previous
Next
Cookie Settings
|
Terms and Conditions
|
Legal Disclaimer
|
Privacy Policy
|
Accessibility